151
Dry eye disease compounds currently under evaluation in
clinical trials
BasilioColligris, JesúsPintor*
Departamento de Bioquímica y Biología Molecular IV, Facultad de Óptica y Optometría, Universidad
ComplutensedeMadrid,Madrid, España.
*e-‐mail:
An. Real Acad. Farm. Vol 80, Nº 1(2014), pág. 151-‐178
ABSTRACT
Dry eye syndrome is a common disorder provoking changes in tear quantity and
composition being the most common ophthalmic manifestation of systemic
inflammatory diseases. Untreated dry eye could cause increased risk of ocular
infection, corneal ulcer and blindness. Only a fewdrugs are authorized so far for
the treatment of dry eye disease and the possibilities of evolution in this sector
are immense. Accordingly, the future tendency is towards the development of
drugs to control the inflammation or stimulate the mucin and tear secretion. A
significant number of newpotential solutions areunder development or placed in
the pharmaceutical pipeline, promising better results and lesser side effects, but
still leaving unattended themain causes of the disease. In this article, we review
the corresponding literature, recent clinical trials data and patents concerning
future pharmaceutical compounds for dry eye disease treatment, presenting the
newstrategicmovementsof thepharmaceutical industry.
Keywords:
Dry eye; anti-‐inflammatory; keratoconjunctivitis sicca; keratitis sicca;
xerophthalmia;mucinsecretion; tear secretion;NSAID.
REVISIÓN
